Avacta Group PLC Result of Annual General Meeting (6792N)
22 January 2019 - 2:40AM
UK Regulatory
TIDMAVCT
RNS Number : 6792N
Avacta Group PLC
21 January 2019
21 January 2019
Avacta Group plc
("Avacta", the "Group" or the "Company")
Result of Annual General Meeting
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and reagents announces that at the Annual General
Meeting held earlier today, all resolutions were duly passed.
The full text of each resolution is set out in the Notice of
Annual General Meeting, included in the 2018 Annual Report, which
is available on the Company's website www.avacta.com.
- Ends -
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0) 844 414 0452
Alastair Smith, Chief Executive https://www.avacta.com
Officer
Tony Gardiner, Chief Financial Officer
finnCap Ltd Tel: +44 (0) 207 220 0500
Geoff Nash / Giles Rolls - Nominated www.finncap.com
Adviser
Tim Redfern - ECM
Tel: +44 (0) 203 705 9318
WG Partners Tel: +44 (0) 203 705 9217
Nigel Birks / Nigel Barnes www.wgpartners.co.uk
David Wilson / Claes Spang
Turner Pope Investments Tel: 020 3621 4120
James Pope james@turnerpope.com
Zyme Communications (Trade and Regional Tel: +44 (0)7787 502 947
Media) katie.odgaard@zymecommunications.com
Katie Odgaard
Yellow Jersey (Financial Media and Tel: +44 (0)7764 947137
IR) Tel: +44 (0)7544 275882
Sarah Hollins avacta@yellowjerseypr.com
Harriet Jackson
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite
their shortcomings. Affimer(R) technology has been designed to
address many of these negative performance issues, principally; the
time taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer(R) technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on immuno-oncology as well as partnered development
programmes. Avacta is commercialising non-therapeutic Affimer(R)
reagents through licensing to developers of life sciences research
tools and diagnostics.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGPGUPWGUPBGAG
(END) Dow Jones Newswires
January 21, 2019 10:40 ET (15:40 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024